A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia

In the current phase 1 study, the combination of brentuximab vedotin, an antibody‐drug conjugate targeting CD30, and re‐induction chemotherapy (mitoxantrone, etoposide, and cytarabine) is found to be…

Read the full article here

Related Articles